Previous 10 | Next 10 |
Point Roberts, WA and Delta, BC - August 27, 2021 (Investorideas.com Newswire) Investorideas.com , a global news source and expert investing resource, announces its weekly roundup of stocks to watch in biotech, cannabis, mining, cleantech and psychedelics. Today's stocks have been added...
- IPO raised an aggregate of approximately $149.1 million in gross proceeds - Strong cash position of $198.6 million to be used to deliver expected key value-creating milestones and fund operations through 2023 - Lead program, CYT-0851, advancing in Phase 1 dose escalation trial...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT), a company focused on the discovery and development of next-generation synthetically lethal therapies for cancer, announced that its President and Chief Executive Officer Markus Renschler, MD will participate in the 2021 W...
After four back-to-back sessions of gains, the healthcare stocks in the S&P 500 finished ~0.5% higher this week to outperform the ~0.4% loss recorded by the broader index over the past five-day period. A major industry event on Alzheimer’s disease dominated heal...
Artystarty/iStock via Getty Images The healthcare stocks in the S&P 500 finished ~2.2% higher this week to outperform the ~2.0% gain recorded by the broader index over the past five-day period. While the stocks weighed down by their alleged involvement in the U.S. opioid crisis ...
Recently IPO’d pharma company Cyteir Therapeutics (CYT) continued its losing streak to the fifth day as the stock dropped ~11.9% to record a new low since its IPO.The clinical-stage oncology company expected ~$133M in gross proceeds in June after pricing the public offer of ~...
Gainers:Chembio Diagnostics CEMI +199%.NeuroMetrix NURO +187%.Lexaria Bioscien LEXX +55%.Studio City International MSC +43%.Forward Pharma A/S (FWP) +30%.Meta Materials (MMAT) +28%.Cassava Sciences SAVA +27%.Beyond Air (XAIR) +22%.SigmaTron International SGMA +21...
sanjeri/E+ via Getty Images BofA Securities has initiated Cyteir Therapeutics ([[CYT]] -2.5%) as a buy with a $23 price target (20% upside). Cyteir is focused on the development of next-generation synthetically lethal therapies to treat cancer. Analyst Tazeen Ahmad says the company's lead ass...
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead It's that time again, as second-quarter earnings season kicks off in earnest with the usual early reports from banks - J...
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
News, Short Squeeze, Breakout and More Instantly...
Cyteir Therapeutics Inc. Company Name:
CYT Stock Symbol:
NASDAQ Market:
Initial data from Phase 1 combination with capecitabine in advanced ovarian cancer are expected in mid-2023 Dose for the Phase 1 combination trials identified as 400mg daily Ended 2022 with approximately $147 million in cash; Projected cash runway into 2026 Cyteir Therapeutics, ...
Cyteir Therapeutics, Inc. (“Cyteir”) (Nasdaq: CYT) a clinical stage oncology company today announced the promotion of David Gaiero to Chief Financial Officer (CFO). David was previously Vice President of Finance at Cyteir. As CFO, David will continue to manage the finance department...
- Encouraging early clinical results observed in treating ovarian cancer with CYT-0851 combination therapy - Strategic prioritization of clinical development of CYT-0851 combination therapy for ovarian cancer, together with deferral of other development activities, is expected to extend cash ...